Literature DB >> 31223436

LRRK2 Kinase Inhibitors as Possible Therapy for Parkinson's Disease and Other Neurodegenerative Disorders.

Ahmed F Abdel-Magid1.   

Abstract

Entities:  

Year:  2019        PMID： 31223436      PMCID： PMC6580372          DOI： 10.1021/acsmedchemlett.9b00216

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN： 1948-5875            Impact factor:   4.345


× No keyword cloud information.
  4 in total

Review 1.  Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016).

Authors:  Paul Galatsis
Journal:  Expert Opin Ther Pat       Date:  2017-01-31       Impact factor: 6.674

Review 2.  Achieving neuroprotection with LRRK2 kinase inhibitors in Parkinson disease.

Authors:  Andrew B West
Journal:  Exp Neurol       Date:  2017-07-29       Impact factor: 5.330

Review 3.  New Frontiers in Parkinson's Disease: From Genetics to the Clinic.

Authors:  Lamya S Shihabuddin; Patrik Brundin; J Timothy Greenamyre; Diane Stephenson; S Pablo Sardi
Journal:  J Neurosci       Date:  2018-10-31       Impact factor: 6.167

Review 4.  LRRK2 Kinase Inhibition as a Therapeutic Strategy for Parkinson's Disease, Where Do We Stand?

Authors:  Jean-Marc Taymans; Elisa Greggio
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.